Clyde Biosciences enables earlier detection of cardiovascular risk, empowering pharmaceutical and biotech teams to make smarter decisions for clinical translation
Clyde Biosciences enables earlier detection of cardiovascular risk, empowering pharmaceutical and biotech teams to make smarter decisions for clinical translation. Their CellOPTIQ® platform delivers predictive, functional cardiac safety data using a human iPSC-derived cardiac model, enabling faster and more accurate assessment of cardiotoxicity.